Physician

Suzan R Merten, M.D.

According to 2025 Medicare claims, Suzan Merten, M.D. (NPI: 1669448692) practices medical oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (NPI: 1487621496; TIN: 541922084) and primary practice location at 24014-2419. Merten is affiliated with the Doctors Connected (ACO ID: A4949), participating under the MSSP model.

Merten's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 929 traditional Medicare patients, billed 165,270 HCPCS/CPT codes, and received $2,912,126 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,916 prescription claims across 521 beneficiaries totaling $5,598,174 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 83 claims. Open Payments data shows 1 records totaling $33. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,236,070 to $5,598,174. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,015	285,929	$2,808,359
2016	1,044	193,365	$2,895,429
2017	1,099	183,028	$3,254,463
2018	1,067	220,227	$3,548,030
2019	1,049	240,732	$4,108,312
2020	1,045	256,147	$4,637,878
2021	1,078	211,635	$4,401,850
2022	1,039	216,002	$4,171,728
2023	1,014	218,889	$3,544,442
2024	929	165,270	$2,912,126

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	295	1,532	$1,236,070
2016	307	1,608	$1,052,299
2017	324	1,576	$1,907,756
2018	322	1,412	$1,551,358
2019	301	1,196	$1,782,717
2020	343	1,233	$3,010,099
2021	380	1,188	$3,161,739
2022	397	1,287	$3,203,559
2023	441	1,432	$4,535,395
2024	521	1,916	$5,598,174

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	51	267	$103,156
2016	40	142	$43,089
2017	43	133	$36,522
2018	23	103	$14,724
2019	90	237	$26,200
2020	59	196	$15,055
2021	66	200	$15,012
2022	44	126	$4,828
2023	38	88	$9,116
2024	11	83	$1,979

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	273	509	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	424	661	$59
80053	Blood test, comprehensive group of blood chemicals	446	975	$10
36415	Insertion of needle into vein for collection of blood sample	398	622	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	491	1,406	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	47	1,316	$675,530
Revlimid	Lenalidomide	28	784	$593,608
Verzenio	Abemaciclib	34	952	$511,797
Ibrance	Palbociclib	24	672	$426,026
Calquence	Acalabrutinib Maleate	23	690	$414,616

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	35	$1,213
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	29	$527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$238

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$33	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Suzan R. Merten, M.D.?

Tedicare shows public-source Medicare data for Suzan R. Merten, M.D. (NPI 1669448692), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Suzan R. Merten, M.D. have ACO affiliation data?

Suzan R. Merten, M.D. is shown with ACO affiliation data for Doctors Connected (MSSP, ACO ID A4949).

What billing organization is linked to Suzan R. Merten, M.D.?

Suzan R. Merten, M.D. is linked to ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (billing NPI 1487621496) in the available physician profile data.

Does Suzan R. Merten, M.D. have Open Payments data?

Suzan R. Merten, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.